Explore the Potential with AI-Driven Innovation
Our detailed focused library is generated on demand with advanced virtual screening and parameter assessment technology powered by the Receptor.AI drug discovery platform. This method surpasses traditional approaches, delivering compounds of better quality with enhanced activity, selectivity, and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library features a range of promising modulators, each detailed with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Plus, each compound is presented with its ideal docking poses, affinity scores, and activity scores, ensuring a thorough insight.
We use our state-of-the-art dedicated workflow for designing focused libraries for receptors.
Fig. 1. The sreening workflow of Receptor.AI
This process includes extensive molecular simulations of the receptor in its native membrane environment, along with ensemble virtual screening that accounts for its conformational mobility. In the case of dimeric or oligomeric receptors, the entire functional complex is modelled, identifying potential binding pockets on and between the subunits to encompass all possible mechanisms of action.
Key features that set our library apart include:
partner
Reaxense
upacc
P35398
UPID:
RORA_HUMAN
Alternative names:
Nuclear receptor RZR-alpha; Nuclear receptor subfamily 1 group F member 1; RAR-related orphan receptor A; Retinoid-related orphan receptor-alpha
Alternative UPACC:
P35398; P35397; P35399; P45445; Q495X4; Q96H83
Background:
Nuclear receptor ROR-alpha, also known as RAR-related orphan receptor A, plays a pivotal role in various biological processes including embryonic development, cellular differentiation, and metabolism regulation. It binds DNA to modulate the transcription of genes critical for circadian rhythm, lipid metabolism, and immune response.
Therapeutic significance:
The protein's involvement in Intellectual developmental disorder with or without epilepsy or cerebellar ataxia highlights its potential as a target for therapeutic intervention. Understanding the role of Nuclear receptor ROR-alpha could open doors to novel treatments for neurodevelopmental disorders.